Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: analysis of early efficacy and complications.

Division of Vascular Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Journal of Vascular Surgery (Impact Factor: 2.88). 09/2005; 42(3):488-93. DOI: 10.1016/j.jvs.2005.05.014
Source: PubMed

ABSTRACT Endovenous laser therapy (EVLT) and radiofrequency ablation (RFA) are new, minimally invasive percutaneous endovenous techniques for ablation of the incompetent great saphenous vein (GSV). We have performed both procedures at the Mayo Clinic during two different consecutive periods. At the time of this report, no single-institution report has compared RFA with EVLT in the management of saphenous reflux. To evaluate early results, we reviewed saphenous closure rates and complications of both procedures.
Between June 1, 2001, and June 25, 2004, endovenous GSV ablation was performed on 130 limbs in 92 patients. RFA was the procedure of choice in 53 limbs over the first 24-month period of the study. This technique was subsequently replaced by EVLT, which was performed on the successive 77 limbs. The institutional review board approved the retrospective chart review of patients who underwent saphenous ablation. According to the CEAP classification, 124 limbs were C2-C4, and six were C5-C6. Concomitant procedures included avulsion phlebectomy in 126 limbs, subfascial endoscopic perforator surgery in 10, and small saphenous vein ablation in 4 (EVLT in 1, ligation in 1, stripping in 2). Routine postoperative duplex scanning was initiated at our institution only after recent publications reported thrombotic complications following RFA. This was obtained in 65 limbs (50%) (54/77 [70%] of the EVLT group and 11/53 [20.8%] of the RFA group) between 1 and 23 days (median, 7 days).
Occlusion of the GSV was confirmed in 93.9% of limbs studied (94.4% in the EVLT [51/54] and 90.9% in the RFA group [10/11]). The distance between the GSV thrombus and the common femoral vein (CFV) ranged from -20 mm (protrusion in the CFV) to +50 mm (median, 9.5 mm) and was similar between the two groups (median, 9.5 mm vs 10 mm). Thrombus protruded into the lumen of the CFV in three limbs (2.3%) after EVLT. All three patients were treated with anticoagulation. One received a temporary inferior vena cava filter because of a floating thrombus in the CFV. Duplex follow-up scans of these three patients performed at 12, 14, and 95 days, respectively, showed that the thrombus previously identified at duplex scan was no longer protruding into the CFV. No cases of pulmonary embolism occurred. The distance between GSV thrombus and the saphenofemoral junction after EVLT was shorter in older patients (P = .006, r(2) = 0.13). The overall complication rate was 15.4% (20.8% in the EVLT and 7.6% in the RFA group, P =.049) and included superficial thrombophlebitis in 4, excessive pain in 6 (3 in the RFA group), hematoma in 1, edema in 3 (1 in the RFA group), and cellulitis in 2. Except for two of the three patients with thrombus extension into the CFV, none of these adverse effects required hospitalization.
GSV occlusion was achieved in >90% of cases after both EVLT and RFA at 1 month. We observed three cases of thrombus protrusion into the CFV after EVLT and recommend early duplex scanning in all patients after endovenous saphenous ablations. DVT prophylaxis may be considered in patients >50 years old. Long-term follow-up and comparison with standard GSV stripping are required to confirm the durability of these endovenous procedures.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic venous insufficiency (CVI) results from venous hypertension secondary to superficial or deep venous valvular reflux, as well as venous obstruction. The most severe clinical manifestation of CVI is venous leg ulceration that can result in significant morbidity, including venous gangrene and amputation, albeit rare. Treatment modalities are aimed at reducing venous hypertension. Diuretic therapy, although widely used, only provides short-term improvement of the edema but provides no long-term benefit. Compression therapy is the cornerstone in the management of CVI. Compression can be achieved using compression bandaging, compression pumps, or graduated compression stockings. Topical steroid creams may reduce inflammation, venous eczema, and pain in the short term, but they can be detrimental in the long run. Apligraf (a living, bilayered, cell-based product) in conjunction with compression therapy was noted to be more effective in healing venous leg ulcerations, when compared with treatment with compression therapy and zinc paste. Endovascular and surgical techniques that minimize valvular reflux and relieve venous obstruction improve venous hemodynamics, promoting wound healing.
    Techniques in Vascular and Interventional Radiology. 01/2014; 17(2):132–138.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Complaints relating to reflux in the venous system can be addressed by conservative, surgical, or interventional treatment options. The aim of the treatment is to prevent complications and progression of venous disease and to improve patients' quality of life. Endovenous thermal ablation therapies have become the most frequently used type of therapy for saphenous varicose veins. The available endovenous thermal techniques are endovenous laser ablation, radiofrequency ablation, and endovenous steam ablation. In this review, the procedures, indications, and treatment parameters of the three endovenous thermal ablation treatments are discussed as well as their advantages and disadvantages.
    Lasers in Medical Science 09/2013; · 2.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endovenous radiofrequency ablation (RFA) is a safe and effective treatment for varicose veins secondary to saphenous reflux. Deep venous thrombosis (DVT) is a known complication of this procedure. The purpose of this study is to describe the frequency of DVT after RFA and associated predisposing factors. A retrospective analysis was performed using prospectively collected data from December 2008 to December 2011; a total of 277 consecutive office-based RFA procedures were performed at a single institution using the VNUS ClosureFast catheter. Duplex scans were completed 2 weeks post-procedure in all patients. Risk factors assessed for development of DVT included: great vs. small saphenous vein treated, right vs. left side treated, number of RF cycles used, hypercoagulable state, history of DVT, tobacco use, medications (oral contraceptives, aspirin, warfarin, clopidogrel) and vein diameter at the junction of the superficial and deep systems. 72% of the patients were female, 56% were treated on the right side, and 86% were performed on the great saphenous vein (GSV). Mean age was 54 ± 14 (range 23 - 88 years). Three percent of patients had a pre-procedure diagnosis of hypercoagulable state and 8% had a history of previous DVT. On post-procedural US, thrombus protrusion into the deep system without occlusion (Endovascular Heat-Induced Thrombosis, or EHIT) was present in 11 patients (4%). DVT, as defined by thrombus protrusion with complete occlusion of the femoral or popliteal vein, was identified in 2 patients (0.7%). Previous DVT was the only factor associated with post-procedural DVT (p= .018). Although not statistically significant, there was a trend toward higher risk of DVT in small saphenous vein (SSV) treated patients. Factors associated with EHIT alone were male gender (p= .02), SSV treatment (p=.05), aspirin use (p= .008) and factor V Leiden deficiency (p= .01). The use of RFA to treat patients with symptoms due to saphenous reflux involves a small but definite risk of DVT. This study demonstrates that the risk of post-RFA DVT is greater in patients with previous DVT, with a trend towards an increased risk in patients having the SSV treated. Periprocedural anticoagulation may be considered in this subset to reduce the risk of DVT after RFA. Thrombus protrusion without DVT was found to be more likely in patients with hypercoagulability, male gender, SSV treatment, and aspirin use. Additional prospective studies are required to analyze these and other factors which may predict thrombotic events after endovenous RFA.
    Annals of Vascular Surgery 11/2013; · 0.99 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014